We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based Cancer Research Technology (CRT) has extended its collaboration with US pharmaceutical company Merck to discover new cancer drugs targeting the Hippo pathway.